Gottlieb: FDA To Modernize Product Reviews, Consider Illicit Use

FDA is taking steps to modernize its organizational structure and improve coordination among its expert staff, as well as reconsidering its approach to risk-benefit assessment in pre- and postmarket drug reviews, especially in regards to opioids, FDA Commissioner Scott Gottlieb said at a National Press Club luncheon on Friday (Nov. 3). While the commissioner would not talk about specific products, he hinted that drugs containing oxymorphone may be the newest products to face a closer look from the agency due...